載入...
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
BACKGROUND: Cancer vaccine is one of the attractive treatment modalities for patients with castration-resistant prostate cancer (CRPC). However, because of delayed immune responses, its clinical benefits, besides for overall survival (OS), are not well captured by the World Health Organization (WHO)...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3882108/ https://ncbi.nlm.nih.gov/pubmed/24373380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-613 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|